EU: Pivotal Moment For Roche’s Faster-To-Apply Breast Cancer Combo
Patients preferred subcutaneous injection compared to standard intravenous administration
Executive Summary
The European Medicines Agency is this week deciding whether or not to recommend pan-EU marketing approval for Roche’s subcutaneously injected fixed-dose combination of Perjeta and Herceptin. The agency is also deciding on a marketing application for the company's flu antiviral, baloxavir marboxil.
You may also be interested in...
Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.